Glenmark Pharmaceuticals announced the release of a new medication targeting glycemic control and weight-loss in diabetes patients. On Wednesday, the Mumbai-based drug company launched Empagliflozin, a widely acknowledged SGLT2 inhibitor, under the brand name Glempa, alongside fixed-dose combinations Glempa-L and Glempa-M.
About the Author
